EN DE
STOCK COMPARISON

Vertex Pharmaceuticals vs Zura Bio Limited Class A Ordinary Shares: Fair Value & Quality

Both stocks run through our valuation models. Here is how Vertex Pharmaceuticals (VRTX) and Zura Bio Limited Class A Ordinary Shares (ZURA) compare, as of Sep 17, 2026.

As of Sep 17, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the more attractively valued of the two: Vertex Pharmaceuticals trades at $513 versus a fair value of $566 (+10%), while Zura Bio Limited Class A Ordinary Shares trades at $4.61 versus $0.88 (-81%).
Vertex Pharmaceuticals
VRTX · USD · Health Care
+10%
upside to fair value
undervalued
Price$513
Fair Value$566
Quality79/100
Zura Bio Limited Class A Ordinary Shares
ZURA · USD · Health Care
-81%
upside to fair value
overvalued
Price$4.61
Fair Value$0.88
Quality30/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Vertex PharmaceuticalsZura Bio Limited Class A Ordinary Shares
Valuation
28.8×P/E (TTM)—
10.06×P/S (TTM)—
6.59×P/B5.52×
23.8×EV/EBITDA—
1.72×PEG—
+10.3%Fair value upside−80.8%
0.1%Dividend yield—
Profitability
38%Operating margin0%
0.86×EBIT margin trend (5Y)—
24%Return on equity-51%
12%Return on assets-31%
Growth
8%Revenue growth (YoY)0%
10.6%Avg. growth/yr (3Y)—
14.2%Avg. growth/yr (5Y)—
+13.6%Value creation/yr—
Balance & size
357.9×Interest coverage (EBIT/interest)—
0.03×Debt / equity—
$123BMarket cap$561M
healthyGrowth quality—

Vertex Pharmaceuticals leads: 3 to 1 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Vertex Pharmaceuticalsof which business quality 77 · market factors 73 Zura Bio Limited Class A Ordinary Sharesof which business quality 30 · market factors 62
ProfitabilityMargins and returns on capital today
72
0
Quality GrowthAre margins and returns improving?
65
25
CashflowEarnings quality: real cash, not paper profit
79
30
Fin. StrengthBalance sheet, leverage, solvency risk
92
100
InvestmentDisciplined investing over empire-building
58
0
Low VolatilityCalm price path (market factor)
85
50
MomentumPrice trend over the last 3–12 months (market factor)
62
64
52W MomentumDistance to the 52-week high (market factor)
78
75
Net IssuanceShare count: buybacks or dilution?
82
0

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyVertex PharmaceuticalsPrice $513Zura Bio Limited Class A Ordinary SharesPrice $4.61
DCF Models-12%close to the price$453n/a
Earnings-Based+1%close to the price$516n/a
Dividend Discount-99%below the price$7.07n/a
Multiples-46%below the price$278n/a
Asset-Based-90%below the price$49.27-88%below the price$0.54
Growth DCF-32%below the price$348n/a
Economic Profit-51%below the price$254n/a
Growth Earnings+35%above the price$692n/a
Minimum-99%below the price$7.07-88%below the price$0.54
Maximum+35%above the price$692-88%below the price$0.54
Median-39%below the price$313-88%below the price$0.54
Geometric mean-64%below the price$185-88%below the price$0.54

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Vertex Pharmaceuticals: 19 of 26 models see the stock below the current price.

Zura Bio Limited Class A Ordinary Shares: 1 of 1 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Vertex Pharmaceuticals
Price $513
Fair Value $566
Bear $329Bull $1,262
Zura Bio Limited Class A Ordinary Shares
Price $4.61
Fair Value $0.88
Bear $0.59Bull $1.11

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside+10% · above median

Zura Bio Limited Class A Ordinary Shares · Health Care

Quality score30 · bottom 25%
Fair value upside-81% · bottom 25%

Bottom line

As of Sep 17, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the more attractively valued of the two: Vertex Pharmaceuticals trades at $513 versus a fair value of $566 (+10%), while Zura Bio Limited Class A Ordinary Shares trades at $4.61 versus $0.88 (-81%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →
Vertex Pharmaceuticals · Zura Bio Limited Class A Ordinary Shares

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Vertex Pharmaceuticals

Microsoft vs NvidiaApple vs MicrosoftNvidia vs Taiwan Semiconductor ManufacturingApple vs Taiwan Semiconductor Manufacturing

Related to Zura Bio Limited Class A Ordinary Shares

Alphabet Inc Class C vs Meta PlatformsMicrosoft vs Taiwan Semiconductor ManufacturingCisco Systems vs NvidiaApple vs Cisco Systems
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.